Patent · US Active

Compositions, use, and method for CDK2-PROTACs for cancer therapy and hearing loss

US11744896B2 · kind B2 · utility

1Cited by

0References

7Claims

0Family size

Assignees

CREIGHTON UNIVERSITY · US
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (TENNESSEE NOT FOR PROFIT CORPORATION) · US

Inventors

Jian Zuo · Beijing, CN
Santanu Hati · Omaha, US
Marisa Laura Zallocchi · Omaha, US
Robert Alan HAZLITT · Broomfield, US
Jaeki Min · Seojong-myeon, KR

Key dates

Filing date	Sep 28, 2021
Grant date	Sep 5, 2023
Priority date	—
Expiry date	Sep 28, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P27/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are CDK2-PROTAC compounds and pharmaceutical compositions thereof that can be used for specific degradation of the cyclin-dependent kinase 2 (CDK2) protein, for treatment of cancers and other CDK2 related diseases as well as for prevention and treatment of hearing loss.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.